Michael Secora
CIK 1855980 · View on SEC EDGAR ↗
First SEC filing: April 15, 2021 · Latest: April 15, 2021
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 14, 2024 | RXRX | S 10b5-1 | 1,067 | $10.98 | $11,716 | 1,186,351 Direct | -0.09% | Disposed | -70.4% (price as of 2026-08-19) |
| Feb. 14, 2024 | RXRX | S 10b5-1 | 23,933 | $10.43 | $249,621 | 1,187,418 Direct | -1.98% | Disposed | -68.9% (price as of 2026-08-19) |
| Feb. 13, 2024 | RXRX | S 10b5-1 | 25,000 | $9.86 | $246,500 | 1,173,851 Direct | -2.09% | Disposed | -67.1% (price as of 2026-08-19) |
| Jan. 17, 2024 | RXRX | S 10b5-1 | 25,000 | $10.25 | $256,250 | 981,014 Direct | -2.49% | Disposed | -68.3% (price as of 2026-08-19) |
| Jan. 16, 2024 | RXRX | S 10b5-1 | 25,000 | $10.45 | $261,250 | 968,514 Direct | -2.52% | Disposed | -68.9% (price as of 2026-08-19) |
| Dec. 13, 2023 | RXRX | S 10b5-1 | 25,000 | $7.59 | $189,750 | 956,014 Direct | -2.55% | Disposed | -57.2% (price as of 2026-08-19) |
| Dec. 12, 2023 | RXRX | S 10b5-1 | 25,000 | $7.39 | $184,750 | 943,514 Direct | -2.58% | Disposed | -56.1% (price as of 2026-08-19) |
| Nov. 15, 2023 | RXRX | S 10b5-1 | 4,700 | $7.62 | $35,814 | 938,186 Direct | -0.50% | Disposed | -57.4% (price as of 2026-08-19) |
| Nov. 15, 2023 | RXRX | S 10b5-1 | 20,300 | $7.25 | $147,175 | 942,886 Direct | -2.11% | Disposed | -55.2% (price as of 2026-08-19) |
| Nov. 14, 2023 | RXRX | S 10b5-1 | 25,000 | $6.32 | $158,000 | 925,686 Direct | -2.63% | Disposed | -48.7% (price as of 2026-08-19) |
| Oct. 11, 2023 | RXRX | S 10b5-1 | 25,000 | $6.85 | $171,250 | 913,186 Direct | -2.66% | Disposed | -52.6% (price as of 2026-08-19) |
| Oct. 10, 2023 | RXRX | S 10b5-1 | 25,000 | $7.07 | $176,750 | 900,686 Direct | -2.70% | Disposed | -54.1% (price as of 2026-08-19) |
| Sept. 13, 2023 | RXRX | S 10b5-1 | 25,000 | $8.69 | $217,250 | 888,186 Direct | -2.74% | Disposed | -62.7% (price as of 2026-08-19) |
| Sept. 12, 2023 | RXRX | S 10b5-1 | 25,000 | $8.43 | $210,750 | 875,686 Direct | -2.78% | Disposed | -61.5% (price as of 2026-08-19) |
| Aug. 16, 2023 | RXRX | S 10b5-1 | 25,000 | $8.90 | $222,500 | 863,186 Direct | -2.81% | Disposed | -63.5% (price as of 2026-08-19) |
| Aug. 15, 2023 | RXRX | S 10b5-1 | 25,000 | $9.27 | $231,750 | 850,686 Direct | -2.85% | Disposed | -65.0% (price as of 2026-08-19) |
| July 19, 2023 | RXRX | S 10b5-1 | 9,859 | $16.00 | $157,744 | 842,913 Direct | -1.16% | Disposed | -79.7% (price as of 2026-08-19) |
| July 19, 2023 | RXRX | S 10b5-1 | 13,150 | $15.36 | $201,984 | 852,772 Direct | -1.52% | Disposed | -78.9% (price as of 2026-08-19) |
| July 19, 2023 | RXRX | S 10b5-1 | 1,991 | $14.36 | $28,591 | 865,922 Direct | -0.23% | Disposed | -77.4% (price as of 2026-08-19) |
| July 18, 2023 | RXRX | S 10b5-1 | 500 | $14.05 | $7,025 | 830,413 Direct | -0.06% | Disposed | -76.9% (price as of 2026-08-19) |
| July 18, 2023 | RXRX | S 10b5-1 | 24,500 | $13.62 | $333,690 | 830,913 Direct | -2.86% | Disposed | -76.2% (price as of 2026-08-19) |
| June 14, 2023 | RXRX | S 10b5-1 | 25,000 | $10.07 | $251,750 | 817,913 Direct | -2.97% | Disposed | -67.8% (price as of 2026-08-19) |
| June 13, 2023 | RXRX | S 10b5-1 | 25,000 | $9.93 | $248,250 | 805,413 Direct | -3.01% | Disposed | -67.3% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 14, 2024 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Feb. 13, 2024 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Feb. 9, 2024 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (348,380) | $10.09 | Feb. 9, 2034 | 348,380 | Acquired |
| Jan. 17, 2024 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Jan. 16, 2024 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Dec. 13, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Dec. 12, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Nov. 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Nov. 14, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Oct. 11, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Oct. 10, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Sept. 13, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Sept. 12, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Aug. 16, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Aug. 15, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| July 19, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| July 18, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| June 14, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| June 13, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (37,500) | $2.22 | March 3, 2030 | 37,500 | Disposed |
| Feb. 1, 2023 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (404,857) | $8.55 | Feb. 1, 2033 | 404,857 | Acquired |
| Feb. 4, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (3,914) | $11.40 | Feb. 4, 2032 | 3,914 | Acquired |
| Feb. 4, 2022 | RXRX | Stock Option (Right to Buy) | Class A Common Stock (116,684) | $11.40 | Feb. 4, 2032 | 116,684 | Acquired |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Class A Common Stock [F1] (1,500,000) | $2.22 | March 30, 2030 | 1,500,000 | Acquired |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Class A Common Stock [F1] (820,313) | $2.22 | March 30, 2030 | 820,313 | Acquired |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Common Stock [F1] (1,500,000) | $2.22 | March 30, 2030 | 1,500,000 | Disposed |
| April 20, 2021 | RXRX | Stock Option (Right to Buy) | Common Stock [F1] (820,313) | $2.22 | March 30, 2030 | 820,313 | Disposed |
| April 20, 2021 | RXRX | Series D Preferred Stock | Common Stock [F1] (149,077) | — | — | 149,077 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 4 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| April 15, 2021 | RXRX | Common Stock [F1] | 379,685 | Direct |
| April 15, 2021 | RXRX | Series D Preferred Stock→ Common Stock [F1] (149,077) | 149,077 | Direct |
| April 15, 2021 | RXRX | Stock Option (Right to Buy)→ Common Stock [F1] (820,313) | 820,313 | Direct |
| April 15, 2021 | RXRX | Stock Option (Right to Buy)→ Common Stock [F1] (1,500,000) | 1,500,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
RXRX
CFO| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $475,000 | — | $1,757,577 | $2,233,116 | — | — | $577,813 | $5,043,506 |
| 2023 | $435,583 | — | $1,730,759 | $2,153,839 | $174,369 | — | $19,830 | $4,514,381 |
| 2020 | $170,833 | $63,000 | — | $3,431,798 | $15,357 | — | $37,500 | $3,718,488 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.